FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972471174> ?p ?o ?g. }

• W2972471174 endingPage "103" @default.
• W2972471174 startingPage "103" @default.
• W2972471174 abstract "Aim. To study the changes in expenses for the usage of the novel medication serelaxine in treatment of decompensated chronic heart failure. Material and methods. At the core of study — buit-up Mark model that takes into consideration two scenarios of the disease course in patients with decompensated CHF: the usage of standard treatment and standard treatment with serelaxine add-on. Probability of the shift from one condition to another for both groups is calculated based on the results of international clinical trials Pre-Relax-AHF and Relax-AHF as by the data of Russian registry ORAKUL-RF. The sources of information on the price of the resources involved were open. As the whole data was not completely comparable in the build-up of the model we made some presuppositions: time hoirizon of observation — 1 year; results of Pre- Relax-AHF and Relax-AHF extrapolated to 1 year; serelaxine was prescribed only in the first episode of CHF decompensation therapy; mean rate of deaths in decompensated CHF in all age groups was the same; dynamics of mortality inside the each time cutoff (1 month, 2-6 months, 7-12 months) was similar. Except of the direct medical expenses the followinf were also calculated: amount of undercollected GDP as a result of economically active patients death; expenses for repeated hospitalizations; expenses for emergency calls; expenses for the treatment of heart failure exacerbation; size of undercollected GDP as a result of no-show of the patient at workplace for economically active patients. Results. Expenses for hospitalization and emergency calls in serelaxine group due to lower rate of hospitalizations were almost two times lower comparing to the standard therapy group: 40,9 and 19,3 mln. rubles per 1000 patients, respectively. While using serelaxine the GDP losses due to temporary disability (the size of undercollected GDP) in the group of 1000 patients decreased by 11,5 mln. rubles, or 50%, and if to include the death related losses — by 29,3 mln. rubles (36,5%) by 1 year. Additional expenses for drug therapy of heart failure by serelaxine are compensated by the decrease of general expenses (including additional therapy by serelaxine) by 7,4-28% in patients of economically active age with decompensated CHF. Conclusion. Serelaxine as drug with the main clinical properties as the decrease of general and cardiovascular mortality, positive influence on the level of nephrologic complications and hospitalizations, shows economical superiority in the management of economically active age patients. Currently the use of serelaxine in patients with decompensated CHF might optimize the expenses of Russian healthcare budget related to the treatment of patients with this condition." @default.
• W2972471174 created "2019-09-19" @default.
• W2972471174 creator A5001256835 @default.
• W2972471174 creator A5043755013 @default.
• W2972471174 date "2015-11-27" @default.
• W2972471174 modified "2023-09-25" @default.
• W2972471174 title "CLINICAL AND ECONOMICAL ASPECTS OF NOVEL APPROACHES TO THE TREATMENT OF CHRONIC HEART FAILURE DECOMPENSATION" @default.
• W2972471174 doi "https://doi.org/10.15829/1560-4071-2015-3-103-107" @default.
• W2972471174 hasPublicationYear "2015" @default.
• W2972471174 type Work @default.
• W2972471174 sameAs 2972471174 @default.
• W2972471174 citedByCount "0" @default.
• W2972471174 crossrefType "journal-article" @default.
• W2972471174 hasAuthorship W2972471174A5001256835 @default.
• W2972471174 hasAuthorship W2972471174A5043755013 @default.
• W2972471174 hasBestOaLocation W29724711741 @default.
• W2972471174 hasConcept C121332964 @default.
• W2972471174 hasConcept C126322002 @default.
• W2972471174 hasConcept C164705383 @default.
• W2972471174 hasConcept C177713679 @default.
• W2972471174 hasConcept C194828623 @default.
• W2972471174 hasConcept C2777014857 @default.
• W2972471174 hasConcept C2778198053 @default.
• W2972471174 hasConcept C2778217198 @default.
• W2972471174 hasConcept C2778721985 @default.
• W2972471174 hasConcept C62520636 @default.
• W2972471174 hasConcept C71924100 @default.
• W2972471174 hasConceptScore W2972471174C121332964 @default.
• W2972471174 hasConceptScore W2972471174C126322002 @default.
• W2972471174 hasConceptScore W2972471174C164705383 @default.
• W2972471174 hasConceptScore W2972471174C177713679 @default.
• W2972471174 hasConceptScore W2972471174C194828623 @default.
• W2972471174 hasConceptScore W2972471174C2777014857 @default.
• W2972471174 hasConceptScore W2972471174C2778198053 @default.
• W2972471174 hasConceptScore W2972471174C2778217198 @default.
• W2972471174 hasConceptScore W2972471174C2778721985 @default.
• W2972471174 hasConceptScore W2972471174C62520636 @default.
• W2972471174 hasConceptScore W2972471174C71924100 @default.
• W2972471174 hasIssue "3" @default.
• W2972471174 hasLocation W29724711741 @default.
• W2972471174 hasLocation W29724711742 @default.
• W2972471174 hasOpenAccess W2972471174 @default.
• W2972471174 hasPrimaryLocation W29724711741 @default.
• W2972471174 hasRelatedWork W2061473108 @default.
• W2972471174 hasRelatedWork W2153527305 @default.
• W2972471174 hasRelatedWork W2157072716 @default.
• W2972471174 hasRelatedWork W2276850597 @default.
• W2972471174 hasRelatedWork W2355594703 @default.
• W2972471174 hasRelatedWork W2361407492 @default.
• W2972471174 hasRelatedWork W2369469722 @default.
• W2972471174 hasRelatedWork W2920551789 @default.
• W2972471174 hasRelatedWork W3194172810 @default.
• W2972471174 hasRelatedWork W4323807298 @default.
• W2972471174 isParatext "false" @default.
• W2972471174 isRetracted "false" @default.
• W2972471174 magId "2972471174" @default.
• W2972471174 workType "article" @default.